Shire PLC (NASDAQ:SHPG) fell 2.1% during trading on Monday . The stock traded as low as $196.00 and last traded at $196.59, with a volume of 536,627 shares. The stock had previously closed at $200.87.

Several brokerages have commented on SHPG. TheStreet cut shares of Shire PLC to a “hold” rating in a research report on Thursday. Zacks Investment Research upgraded shares of Shire PLC from a “sell” rating to a “hold” rating in a research report on Thursday. RBC Capital Markets reiterated an “outperform” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Finally, Leerink Swann reiterated an “outperform” rating and issued a $231.00 price target (up from $213.00) on shares of Shire PLC in a research report on Wednesday, August 3rd. Four equities research analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $237.41.

The company has a market capitalization of $44.91 billion and a PE ratio of 41.00. The firm has a 50 day moving average of $188.48 and a 200-day moving average of $176.89.

Shire PLC (NASDAQ:SHPG) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.35. The company earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. During the same period in the previous year, the company posted $2.63 EPS. The company’s quarterly revenue was up 55.9% compared to the same quarter last year. Equities research analysts predict that Shire PLC will post $12.78 earnings per share for the current year.

Several large investors have added to or reduced their stakes in SHPG. Advisors Asset Management Inc. raised its stake in Shire PLC by 14.1% in the fourth quarter. Advisors Asset Management Inc. now owns 6,521 shares of the biopharmaceutical company’s stock worth $1,337,000 after buying an additional 805 shares in the last quarter. Bank of Montreal Can raised its stake in Shire PLC by 50.4% in the fourth quarter. Bank of Montreal Can now owns 11,469 shares of the biopharmaceutical company’s stock worth $2,352,000 after buying an additional 3,841 shares in the last quarter. Marshall Wace LLP acquired a new stake in Shire PLC during the fourth quarter worth approximately $7,831,000. BlackRock Advisors LLC raised its stake in Shire PLC by 11.3% in the fourth quarter. BlackRock Advisors LLC now owns 515,531 shares of the biopharmaceutical company’s stock worth $105,684,000 after buying an additional 52,220 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in Shire PLC by 12.8% in the fourth quarter. Jennison Associates LLC now owns 7,196,669 shares of the biopharmaceutical company’s stock worth $1,475,317,000 after buying an additional 819,188 shares in the last quarter.

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.